文献速递肺外科

磨玻璃影特征肺腺癌病理肿瘤浸润与预后的预测因素

Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma.
PubMed 文献 · Ann Thorac Surg · 2018-08-08

该研究回顾性分析复旦大学附属上海肿瘤中心736例患者841个磨玻璃影结节的资料,评估影像学测量对病理浸润和预后的预测价值。结果显示影像学测量不能精确预测肿瘤浸润和预后,仅依据薄层CT制定治疗策略不恰当。

要点

  • 肿瘤浸润是5年肺癌特异性无复发生存的唯一独立预测因素。
  • 部分实性成分、大实变尺寸和大肿瘤尺寸与病理浸润性腺癌相关。
  • 影像学测量不能精确预测肿瘤浸润和预后,仅凭薄层CT制定策略不恰当。

核心结论

  • 影像学测量不能精确预测肿瘤浸润和预后,仅依据薄层CT发现为磨玻璃影肿瘤制定治疗策略是不恰当的。

研究设计与样本

  • 回顾性评估在复旦大学附属上海肿瘤中心接受手术治疗的影像学磨玻璃影结节患者的医疗记录。
  • 共纳入736例患者和841个磨玻璃影结节。
  • 研究终点为影像学测量(实变-肿瘤比值、实变大小和肿瘤大小)对病理肺腺癌的预测价值和预后意义。

主要发现

  • 5年肺癌特异性无复发生存率为95.76%(95%CI 93.01%至97.44%),5年肺癌特异性总生存率为98.99%(95%CI 97.69%至99.57%)。
  • 多变量分析显示肿瘤浸润(浸润性腺癌 vs 原位腺癌/微浸润性腺癌,p=0.020)是5年肺癌特异性无复发生存的唯一独立预测因素;浸润性腺癌与更高的复发风险相关(HR 15.98,95%CI 1.55至164.35)。
  • Kaplan-Meier分析显示仅肿瘤浸润状态(浸润性腺癌 vs 原位腺癌/微浸润性腺癌,p=0.003)可预测5年肺癌特异性总生存,浸润性腺癌的总生存差于原位腺癌和微浸润性腺癌。
  • 部分实性成分(OR 9.09,95%CI 2.71至30.47,p=0.000)、大实变尺寸(OR 3.11,95%CI 1.03至9.40,p=0.045)和大肿瘤尺寸(OR 5.48,95%CI 2.68至11.19,p=0.000)与病理浸润性腺癌相关。
  • 对于≤20 mm的浸润性腺癌,肺段切除术和肺叶切除术的5年肺癌特异性无复发生存优于楔形切除术,但差异无统计学意义(p=0.367);三种手术方式的5年肺癌特异性总生存相似(p=0.834)。

临床怎么用

  • 原文结论认为仅依据薄层CT发现为磨玻璃影肿瘤制定治疗策略是不恰当的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We make surgical strategies for ground glass opacity (GGO) nodules currently based on thin-section (TS) computed tomography (CT) findings. Whether radiologic measurements could precisely predict tumor invasion and prognosis of GGO-featured lung adenocarcinoma is uncertain. METHODS: We retrospectively evaluated medical records of patients with radiologic GGO nodules undergoing a surgical procedure at Fudan University Shanghai Cancer Center. The study endpoints were the predictive value and prognostic significance of radiologic measurements (consolidation-to-tumor ratio value, consolidation size, and tumor size) for pathologic lung adenocarcinoma. RESULTS: In this study 736 patients and 841 GGO nodules were included. Five-year lung cancer-specific regression-free survival (LCS-RFS) rate was 95.76% (95% confidence interval [CI], 93.01% to 97.44%). The 5-year LCS overall survival (OS) rate was 98.99% (95% CI, 97.69% to 99.57%). Multivariable analysis showed that tumor invasion (invasive adenocarcinoma [IAD] vs adenocarcinoma in situ [AIS]/minimally invasive adenocarcinoma [MIA], p = 0.020) was the only independent predictor for 5-year LCS-RFS. IAD (hazard ratio, 15.98; 95% CI, 1.55 to 164.35) was correlated with a higher risk of recurrence. Kaplan-Meier analysis showed that only tumor invasion status (IAD vs AIS/MIA, p = 0.003) could predict 5-year lung cancer-specific overall survival (LCS-OS), and IAD had a worse LCS-OS than AIS and MIA. A part-solid component (odds ratio [OR], 9.09; 95% CI, 2.71 to 30.47; p = 0.000), large consolidation size (OR, 3.11; 95% CI, 1.03 to 9.40; p = 0.045), and large tumor size (OR, 5.48; 95% CI, 2.68 to 11.19; p = 0.000) were associated with pathologic IAD. For IAD ≤ 20 mm, segmentectomy and lobectomy had better 5-year LCS-RFS than wedge resection, although the difference was statistically insignificant (p = 0.367). The three types of surgeries provided the similar 5-year LCS-OS (p = 0.834). CONCLUSIONS: Radiologic measurements could not precisely predict tumor invasion and prognosis. Making treatment strategies solely according to TS-CT findings for GGO tumor is inappropriate.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ye T, Deng L, Xiang J, et al. Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma. Ann Thorac Surg. 2018. PMID: 30096292. doi:10.1016/j.athoracsur.2018.06.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。